Metabolic influences that regulate dendritic cell function in tumors

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Dong, Han ^a   Bullock, Timothy N J ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Activation; Cancer immunotherapy; Dendritic cell; Glycolysis; Lipid metabolism; Metabolism; Oxidative phosphorylation; Tumor associated dendritic cell

Indexed keywords

CD86 ANTIGEN; FUMARATE HYDRATASE; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCAVENGER RECEPTOR; SUCCINATE DEHYDROGENASE; T LYMPHOCYTE RECEPTOR; TRIACYLGLYCEROL;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL FUNCTION; DENDRITIC CELL; GLYCOLYSIS; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; METABOLISM; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84895521323     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00024     Document Type: Review

References (76)

1. Waithman J, Allan RS, Kosaka H, Azukizawa H, Shortman K, Lutz MB, et al. Skin-derived dendritic cells can mediate deletional tolerance of class I-restricted self-reactive T cells. J Immunol (2007) 179:4535-41.
2. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev (2003) 192:161-80. doi: 10.1034/j.1600-065X.2003.00009.x.
3. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol (2005) 5:617-28. doi:10.1038/nri1670.
4. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity (2008) 29:325-42. doi:10.1016/j.immuni.2008.08.006.
5. Bullock TN, Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol (2005) 174:710-7.
6. Van Deusen KE, Rajapakse R, Bullock TN. CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses. J Leukoc Biol (2010) 87:477-85. doi:10.1189/jlb.0809535.
7. Feau S, Garcia Z, Arens R, Yagita H, Borst J, Schoenberger SP. The CD4(+) T-cell help signal is transmitted from APC to CD8(+) T-cells via CD27-CD70 interactions. Nat Commun (2012) 3:948. doi:10.1038/ncomms1948.
8. Hammer GE, Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol (2013) 31:743-91. doi:10.1146/annurev-immunol-020711-074929.
9. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 39:38-48. doi:10.1016/j.immuni.2013.07.004.
10. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 10:7466-74. doi:10.1158/1078-0432.CCR-04-0684.
11. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol (2007) 178:2763-9.
12. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochem Zeitschr (1924) 152:319-44.
13. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J Mol Med (Berl) (2011) 89:213-20. doi:10.1007/s00109-011-0728-4.
14. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol (2011) 2:49. doi:10.3389/fphar.2011.00049.
15. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 16:769-77. doi:10.1016/S1074-7613(02)00323-0.
16. Palsson-McDermott EM, O'Neill LA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays (2013) 35:965-73. doi:10.1002/bies.201300084.
17. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity (2013) 38:633-43. doi:10.1016/j.immuni.2013.04.005.
18. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood (2010) 115:4742-9. doi:10.1182/blood-2009-10-249540.
19. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 461:282-6. doi:10.1038/nature08296.
20. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol (2000) 1:151-5. doi:10.1038/77835.
21. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol (2002) 270:169-84.
22. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2004) 279:7370-7. doi:10.1074/jbc.M306793200.
23. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2007) 81:59-66. doi:10.1189/jlb.0306180.
24. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 13:832-42. doi:10.1038/ni.2376.
25. Idoyaga J, Moreno J, Bonifaz L. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands. Cancer Immunol Immunother (2007) 56:1237-50. doi:10.1007/s00262-006-0275-y.
26. Gelman AE, LaRosa DF, Zhang J, Walsh PT, Choi Y, Sunyer JO, et al. The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity (2006) 25:783-93. doi:10.1016/j.immuni.2006.08.023.
27. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (2010) 330:1340-4. doi:10.1126/science.1193494.
28. Ran C, Liu H, Hitoshi Y, Israel MA. Proliferation-independent control of tumor glycolysis by PDGFR-mediated AKT activation. Cancer Res (2013) 73:1831-43. doi:10.1158/0008-5472.CAN-12-2460.
29. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 7:606-19. doi:10.1038/nrg1879.
30. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity (2007) 27:173-8. doi:10.1016/j.immuni.2007.07.008.
31. Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol (2004) 172:4661-5.
32. Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, et al. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol (2012) 189:2151-8. doi:10.4049/jimmunol.1103741.
33. Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol (2010) 185:3919-31. doi:10.4049/jimmunol.1000296.
34. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med (2012) 209:2441-53. doi:10.1084/jem.20112607.
35. Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, et al. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood (2012) 120:1422-31. doi:10.1182/blood-2012-03-419747.
36. Lewis RS, Kolesnik TB, Kuang Z, D'Cruz AA, Blewitt ME, Masters SL, et al. TLR regulation of SPSB1 controls inducible nitric oxide synthase induction. J Immunol (2011) 187:3798-805. doi:10.4049/jimmunol.1002993.
37. Bolanos JP, Peuchen S, Heales SJ, Land JM, Clark JB. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J Neurochem (1994) 63:910-6. doi:10.1046/j.1471-4159.1994.63030910.x.
38. Garedew A, Moncada S. Retraction. Mitochondrial dysfunction and HIF1alpha stabilization in inflammation. J Cell Sci (2012) 125:3254. doi:10.1242/jcs.115949.
39. Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 345:50-4. doi:10.1016/0014-5793(94)00424-2.
40. Hardie DG. Roles of the AMP-activated/SNF1 protein kinase family in the response to cellular stress. Biochem Soc Symp (1999) 64:13-27.
41. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol (2012) 13:251-62. doi:10.1038/nrm3311.
42. Tamas P, Macintyre A, Finlay D, Clarke R, Feijoo-Carnero C, Ashworth A, et al. LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol (2010) 40:242-53. doi:10.1002/eji.200939677.
43. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 112:1822-31. doi:10.1182/blood-2008-02-136325.
44. Challier J, Bruniquel D, Sewell AK, Laugel B. Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity. Immunology (2013) 138:402-10. doi:10.1111/imm.12053.
45. Panther E, Durk T, Ferrari D, Di Virgilio F, Grimm M, Sorichter S, et al. AMP affects intracellular Ca2+ signaling, migration, cytokine secretion and T cell priming capacity of dendritic cells. PLoS One (2012) 7:e37560. doi:10.1371/journal.pone.0037560.
46. Miga AJ, Masters SR, Durell BG, Gonzalez M, Jenkins MK, Maliszewski C, et al. Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol (2001) 31:959-65. doi:10.1002/1521-4141(200103)31:3<::AID-IMMU959>3.0.CO;2-A.
47. Mackey MF, Wang Z, Eichelberg K, Germain RN. Distinct contributions of different CD40 TRAF binding sites to CD154-induced dendritic cell maturation and IL-12 secretion. Eur J Immunol (2003) 33:779-89. doi:10.1002/eji.200323729.
48. Kobayashi T, Walsh PT, Walsh MC, Speirs KM, Chiffoleau E, King CG, et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity (2003) 19:353-63. doi:10.1016/S1074-7613(03)00230-9.
49. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 229:152-72. doi:10.1111/j.1600-065X.2009.00782.x.
50. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 460:103-7. doi:10.1038/nature08097.
51. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2013) 17:113-24. doi:10.1016/j.cmet.2012.12.001.
52. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2006) 107:2013-21. doi:10.1182/blood-2005-05-1795.
53. Nasi A, Fekete T, Krishnamurthy A, Snowden S, Rajnavolgyi E, Catrina AI, et al. Dendritic cell reprogramming by endogenously produced lactic acid. J Immunol (2013) 191:3090-9. doi:10.4049/jimmunol.1300772.
54. Vermeulen M, Giordano M, Trevani AS, Sedlik C, Gamberale R, Fernandez-Calotti P, et al. Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells. J Immunol (2004) 172:3196-204.
55. Tong J, Wu WN, Kong X, Wu PF, Tian L, Du W, et al. Acid-sensing ion channels contribute to the effect of acidosis on the function of dendritic cells. J Immunol (2011) 186:3686-92. doi:10.4049/jimmunol.1001346.
56. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res (2011) 71:6921-5. doi:10.1158/0008-5472.CAN-11-1457.
57. Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des (2012) 18:1319-30. doi:10.2174/138161212799504902.
58. Maroof A, English NR, Bedford PA, Gabrilovich DI, Knight SC. Developing dendritic cells become 'lacy' cells packed with fat and glycogen. Immunology (2005) 115:473-83. doi:10.1111/j.1365-2567.2005.02181.x.
59. Bougneres L, Helft J, Tiwari S, Vargas P, Chang BH, Chan L, et al. A role for lipid bodies in the cross-presentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity (2009) 31:232-44. doi:10.1016/j.immuni.2009.06.022.
60. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 16:880-6. doi:10.1038/nm.2172.
61. Ibrahim J, Nguyen AH, Rehman A, Ochi A, Jamal M, Graffeo CS, et al. Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver. Gastroenterology (2012) 143:1061-72. doi:10.1053/j.gastro.2012.06.003.
62. Weatherill AR, Lee JY, Zhao L, Lemay DG, Youn HS, Hwang DH. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol (2005) 174:5390-7.
63. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature (1997) 386:292-6. doi:10.1038/386292a0.
64. Areschoug T, Gordon S. Scavenger receptors: role in innate immunity and microbial pathogenesis. Cell Microbiol (2009) 11:1160-9. doi:10.1111/j.1462-5822.2009.01326.x.
65. Yi H, Yu X, Gao P, Wang Y, Baek SH, Chen X, et al. Pattern recognition scavenger receptor SRA/CD204 down-regulates Toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood (2009) 113:5819-28. doi:10.1182/blood-2008-11-190033.
66. Yu X, Yi H, Guo C, Zuo D, Wang Y, Kim HL, et al. Pattern recognition scavenger receptor CD204 attenuates Toll-like receptor 4-induced NF-kappaB activation by directly inhibiting ubiquitination of tumor necrosis factor (TNF) receptor-associated factor 6. J Biol Chem (2011) 286:18795-806. doi:10.1074/jbc.M111.224345.
67. Yi H, Guo C, Yu X, Gao P, Qian J, Zuo D, et al. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity. Cancer Res (2011) 71:6611-20. doi:10.1158/0008-5472.CAN-11-1801.
68. Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G, et al. In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. Mol Cancer Ther (2012) 11:2331-41. doi:10.1158/1535-7163.MCT-12-0164.
69. Lerret NM, Rogozinska M, Jaramillo A, Marzo AL. Adoptive transfer of mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors. PLoS One (2012) 7:e41240. doi:10.1371/journal.pone.0041240.
70. Lerret NM, Marzo AL. Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors. Oncoimmunology (2013) 2:e22731. doi:10.4161/onci.22731.
71. Rehman A, Hemmert KC, Ochi A, Jamal M, Henning JR, Barilla R, et al. Role of fatty-acid synthesis in dendritic cell generation and function. J Immunol (2013) 190:4640-9. doi:10.4049/jimmunol.1202312.
72. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity (2012) 36:68-78. doi:10.1016/j.immuni.2011.12.007.
73. Sabbah HH, Stanley WC. Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure. Eur J Heart Fail (2002) 4:3-6. doi:10.1016/S1388-9842(01)00183-0.
74. Sallusto F, Nicolo C, De Maria R, Corinti S, Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med (1996) 184:2411-6. doi:10.1084/jem.184.6.2411.
75. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol (2001) 167:3773-84.
76. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 12:265-77. doi:10.1038/nrc3258.